Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells

被引:89
作者
Mizuarai, Shinji [1 ]
Yamanaka, Kazunori [1 ]
Kotani, Hidehito [1 ]
机构
[1] Merck Res Lab, Banyu Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan
关键词
D O I
10.1158/0008-5472.CAN-05-4629
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tumor suppressor gene p53 is known to induce G(1)-S and G(2)-M Cell cycle arrest and apoptosis by transactivating various wild-type (WT) p53 regulatory genes. Mutational inactivation of p53 is detected in more than half of human cancers, depriving the p53 protein of its tumor-suppressive functions. Recent studies have shown that mutant p53 provides tumor cells with gain-of-function properties, such as accelerated cell proliferation, increased metastasis, and apoptosis resistance. However, the mechanism underlying the elevated tumorigenicity by p53 mutation remains to be elucidated. In the present study, we showed that GEF-H1, a guanine exchange factor-H1 for RhoA, is transcriptionally activated by the induction of mutant p53 proteins, thereby accelerating tumor cell proliferation. Osteosarcoma U2OS cell lines, which express inducible p53 mutants (V157F, R175H, and R248Q), were established, and the expression profiles of each cell line were then analyzed to detect genes specifically induced by mutant p53. We identified GEF-H1 as one of the consensus genes whose expression was significantly induced by the three mutants. The GEF-H1 expression level strongly correlated with p53 status in a panel of 32 cancer cell lines, and GEFH1 induction caused activation of RhoA. Furthermore, growth of mutant p53 cells was dependent on GEF-H1 expression, whereas that of WT p53 cells was not. These results suggest that increased GEF-H1 expression contributes to the tumor progression phenotype associated with the p53 mutation.
引用
收藏
页码:6319 / 6326
页数:8
相关论文
共 43 条
[1]   Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1 [J].
Andreassen, PR ;
Lohez, OD ;
Lacroix, FB ;
Margolis, RL .
MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (05) :1315-1328
[2]   Rho GTPases:: potential candidates for anticancer therapy [J].
Aznar, S ;
Fernández-Valerón, P ;
Espina, C ;
Lacal, JC .
CANCER LETTERS, 2004, 206 (02) :181-191
[3]   Activation of gef-h1, a guanine nucleotide exchange factor for RhoA, by DNA transfection [J].
Brecht, M ;
Steenvoorden, ACM ;
Collard, JG ;
Lufl, S ;
Erz, D ;
Bartram, CR ;
Janssen, JWG .
INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (04) :533-540
[4]   Rescuing the function of mutant p53 [J].
Bullock, AN ;
Fersht, A .
NATURE REVIEWS CANCER, 2001, 1 (01) :68-76
[5]   MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases [J].
deKant, E ;
Heide, I ;
Thiede, C ;
Herrmann, R ;
Rochlitz, CF .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1996, 122 (11) :671-675
[6]   GAIN OF FUNCTION MUTATIONS IN P53 [J].
DITTMER, D ;
PATI, S ;
ZAMBETTI, G ;
CHU, S ;
TERESKY, AK ;
MOORE, M ;
FINLAY, C ;
LEVINE, AJ .
NATURE GENETICS, 1993, 4 (01) :42-46
[7]   DEFINITION OF A CONSENSUS BINDING-SITE FOR P53 [J].
ELDEIRY, WS ;
KERN, SE ;
PIETENPOL, JA ;
KINZLER, KW ;
VOGELSTEIN, B .
NATURE GENETICS, 1992, 1 (01) :45-49
[8]  
Engers R, 2000, INT J CANCER, V88, P369, DOI 10.1002/1097-0215(20001101)88:3<369::AID-IJC8>3.0.CO
[9]  
2-K
[10]  
Frolov A, 2003, MOL CANCER THER, V2, P699